




WHITELAB
GENOMICS

**Unleash the potential
of genomic
medicine**

using AI

Our Company



WhiteLab Genomics

AI for Genomic Medicine

We aim to improve therapeutic target discovery and payload delivery by predicting optimal molecular design for a specific target product profile to expedite and de-risk the development of genomic medicines.

POSITIONING



A specialist in AI for Genomic Medicine, WhiteLab was founded in 2019 with the aim of making revolutionary drugs more accessible and safer for patients.

Based in Paris, Boston, and Montreal, 44 employees (including +20 PhDs)

ALFRED: our proprietary platform combines computational/ structural biology and AI-based models (ML, LLM, GenAI)

Cross therapeutic focus areas (Ophthalmology, Oncology, CNS, Rare diseases, Cardiology)

VALUE PROPOSITION



An ***In silico*** approach, bolstered by **external wet-lab capabilities** and **proprietary data**, delivering industry-leading models with unmatched agility and scalability across therapeutic areas


Addressing both **viral** and **non-viral delivery** for **DNA and RNA-based therapies**

Using **biological data guided rational approaches** to identify biomarkers and design the best vector



We **accelerate** and **de-risk our partners' R&D developments** and help them to reach their target product profile

Our Vision: Revolutionize & Become the AI Leader in Drug Discovery & Development for Genomic Medicines



Genomic Medicine is Revolutionizing Healthcare



Genomic medicine revolutionizes healthcare by **delivering genetic material** to cells, enabling the production of **missing** or **malfunctioning proteins** to **correct disorders**.

What is genomic medicine's **real-world impact**?

✓ **One-shot treatment**
vs lifetime treatment

✓ Genomic medicine is the **fastest growing modality in Biopharma**




Market size today: \$40B



2024-30 CAGR: +17%


✓ Genomic medicines have a phenomenal potential to cure previously untreatable conditions with revolutionary personalized treatments



30+ RNA-based therapies



30+ gene therapies



60+ cell therapies

Deep Domain Expertise at the Convergence of AI & Genomic Medicine

EXECUTIVE TEAM

CO-FOUNDERS



David Del Bourgo, MBA
CEO



Lucia Cingue, PhD
Chief of Staff



Julien Cottineau PhD
CSO



Mathieu Losguardi, CFA
CFO



LEADERSHIP TEAM



55% women/men ratio



Oscar de Felice, PhD
Head of AI



Sara Berthoumieux, PhD
Head of Computational Biology



Dylan Serillon, PhD, PharmD
Head of Protein & Vector Engineering



Patrice Vidal, PhD
Head of Preclinical Research



Domitille Halie, PhD
Head of Scientific Project Management



Dina Zielinski, PhD
Principal Scientist



Timothé Cynober, PharmD
Head of BD & Licensing



Nathan Lee, PhD
Head of Partnerships



SCIENTIFIC AND STRATEGIC BOARD

Nicole, Paulk, PhD

Former Assistant Professor USCF
CEO SIREN Biotechnology



Laurent van Lerberghe, MBA

Balas Invest
Ex-Chief Strategy Officer Sanofi, Abbott, BCG



Magali Richard, PhD

Scientific Advisor
CEO Home Biosciences



Jean-Pascal Tranie


Aloe Private Equity Partner




INVESTORS



Our Platform & Technology



WhiteLab Genomics' Guided Rational Approach



WhiteLab Genomics' R&D pipeline

GENE & RNA-BASED THERAPIES

Target Receptor Identification & Viral Vector Design

CNS

Ophthalmology

CNS

Ophthalmology

Kidney Diseases


Oncology

1 Tech R&D

2 In Silico Design

3 Wet Lab Validation

Our Partners



Non Viral Vector Design

Oncology



Payload Design

Oncology

Cardiac

Pulmonary

Undisclosed



BIOPRODUCTION Optimization

AAV, LV



We Bridge AI with Real-World Biology to Accelerate & De-Risk Genomic Medicine Development

VALUE PROPOSITION

Faster, cost-effective, and clinical phase ready drug candidates

1

35%-40% Faster R&D timelines

speeds up discovery & design from 8-11 years to 5-7 years

2

25%-30% Lower R&D expenses

reduces experimental costs
€25M-€40M vs €35M-€55M

3

20%-30% Higher Success Rate

of candidates advancing from preclinical stages to clinical trials

Precision, Efficacy, and Efficiency

Optimized delivery & dosing, enhanced therapeutic expression, 10,000 fewer candidates to screen



Rational & Guided Design

- **Targeted Vector**
Minimize off-target effects and effective therapeutic dose
- **Known Delivery Mechanism**
Optimize choice of animal models and avoid biological risks



AI & Structural Biology Control

- **Virtual Screening Predictions**
Identify, evaluate & assess millions of candidates
- **Geometric Simulations**
Enabling precise molecular design & interaction analysis



Proprietary Platform & Database


- **Proprietary cell & tissue atlas and ligand database**
- **AI approach** for target identification, vector engineering and payload design
- **4 patent applications** on vector fitness, protein localization, promoter design and innovative peptides



Expertise & Network

- **1st class partnerships**
Leveraging cross-therapeutic expertise & rapid validation
- **In-house in silico expertise**
- **Versatile solutions**
Viral & non-viral vectors for DNA & RNA-based therapies

THANK YOU




WHITELAB

GENOMICS




David DEL BOURGO, MBA
CO-FOUNDER & CEO
ddelbourgo@whitelabgx.com



Timothé CYNOBER, PharmD
GLOBAL HEAD OF BD & L
tcynober@whitelabgx.com



Nathan LEE, PhD
HEAD OF PARTNERSHIPS
nlee@whitelabgx.com



CONTACT US

bd@whitelabgx.com
www.whitelabgx.com



OFFICES

PARIS

Future4Care
8 Rue Jean Antoine de Baïf
75013 Paris, France

BOSTON

Bayer Co.Lab
238 Main St,
Cambridge, MA 02142

MONTREAL

3900-1, Place Ville Marie
Montréal Québec
H3B4M7, Canada